Floatz logo

Opc-34712

Mood Disorders

Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 3Dormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Mood Disorders cohort.

Asset / SponsorPhaseRating
Seroquel®
First Affiliated Hospital of Zhejiang University
Phase 4BBB
Olanzapine
University of Ghana Medical School
Phase 4BBB
Arestin
Pakistan Institute of Living and Learning
Phase 4BBB
FLUOXETINE
University of Ghana Medical School
Phase 4BBB
Paliperidone Palmitate 3-Month Formulation
Luye Pharma Group Ltd.
Phase 3BB

View all 36 →

Same molecule, other indications

Opc-34712 is also rated in:

depressive disorderDormant
A
Indicative ·
82 / 100
View asset →
major depressive disorderDormant
BBB
Indicative ·
75 / 100
View asset →
schizophreniaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →